The potential therapeutic application of SGLT2 inhibitors (SGLT2i), a class of antidiabetic drugs, in the treatment of certain cancers has been investigated based on the observed protein expression and functional activity of SGLT2 in different tumor types [9]. The gene discussed is SLC5A2; the disease is neoplasm.